论文部分内容阅读
目的观察培菲康(双歧杆菌三联活菌散)预防婴幼儿急性呼吸道感染继发腹泻的临床疗效。方法将480例急性呼吸道感染患儿随机分为对照组240例,给予抗生素及对症处理等常规治疗;治疗组240例在对照组治疗的基础上加用培菲康口服。分别观察治疗d3、d5、d7时腹泻的发生率及其严重程度(轻型、中型),并进行统计学分析。结果治疗组d3、d5、d7时腹泻的发生率均低于对照组,差异有统计学意义(P﹤0.01);两组轻性腹泻、中型腹泻的发生率经处理,差异有统计学意义(P﹤0.01)。治疗组病例未见不良反应。结论培菲康能够降低婴幼儿急性呼吸道感染继发腹泻的发生率,有良好的预防作用,值得临床推广使用。
Objective To observe the clinical efficacy of Bifico (Bifidobacterium triple viable powder) in preventing secondary diarrhea in infants with acute respiratory infection. Methods A total of 480 children with acute respiratory tract infection were randomly divided into control group (240 cases), antibiotics and symptomatic treatment. 240 cases in the treatment group were given Peifeikang orally on the basis of the control group. The incidence of diarrhea and its severity (light and medium) at d3, d5 and d7 were observed and statistically analyzed. Results The incidence of diarrhea at d3, d5 and d7 in the treatment group was lower than that in the control group (P <0.01). The incidence of mild diarrhea and moderate diarrhea in the two groups were significantly decreased P <0.01). No adverse reactions were found in the treatment group. Conclusion Pefikan can reduce the incidence of secondary diarrhea in infants and young children with acute respiratory infection, and has a good preventive effect, which is worthy of clinical promotion.